Abstract
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule Factor Xa inhibitors and thrombin inhibitors. The most advanced drugs reviewed include DPC-423, DPC- 602, razaxaban, GSKs 813893, Portolas Xa inhibitors (formerly Millennium), otamixaban, DU-176b, KFA-1982, BAY- 59-7939, DX-9065a, YM-150, LY-517717, Exanta, 3DPs thrombin inhibitors, SSR-182289, LB-30057, LB-30870, BIBR-1048 and Mercks thrombin inhibitors. With their potentially consistent and predictable pharmacological profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Keywords: Venous thromboembolism, Anticoagulant Agent, DPC-423, Razaxaban, antithrombotic, LY-517717
Current Topics in Medicinal Chemistry
Title: Small Molecule Coagulation Cascade Inhibitors in the Clinic
Volume: 5 Issue: 16
Author(s): Eddine Saiah and Chris Soares
Affiliation:
Keywords: Venous thromboembolism, Anticoagulant Agent, DPC-423, Razaxaban, antithrombotic, LY-517717
Abstract: Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule Factor Xa inhibitors and thrombin inhibitors. The most advanced drugs reviewed include DPC-423, DPC- 602, razaxaban, GSKs 813893, Portolas Xa inhibitors (formerly Millennium), otamixaban, DU-176b, KFA-1982, BAY- 59-7939, DX-9065a, YM-150, LY-517717, Exanta, 3DPs thrombin inhibitors, SSR-182289, LB-30057, LB-30870, BIBR-1048 and Mercks thrombin inhibitors. With their potentially consistent and predictable pharmacological profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
Export Options
About this article
Cite this article as:
Saiah Eddine and Soares Chris, Small Molecule Coagulation Cascade Inhibitors in the Clinic, Current Topics in Medicinal Chemistry 2005; 5 (16) . https://dx.doi.org/10.2174/156802605775009702
DOI https://dx.doi.org/10.2174/156802605775009702 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs COVID-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods
Anti-Cancer Agents in Medicinal Chemistry Fc-Independent Phagocytosis: Implications for Intravenous IgG Therapy in Immune Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Applications of FDG-PET/CT in Assessment of Vascular Infection and Inflammation
Current Molecular Imaging (Discontinued) The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Current Drug Targets Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Long-term Treatment of Venous Thromboembolism
Current Vascular Pharmacology Symposium Introduction
Current Cardiology Reviews Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Prediction of Thrombin and Factor Xa Inhibitory Activity with Associative Neural Networks
Current Computer-Aided Drug Design Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics Design and Synthesis of Novel Coumarin Conjugated Acetamides as Promising Anticancer Agents: An <i>In Silico</i> and <i>In Vitro</i> Approach
Anti-Cancer Agents in Medicinal Chemistry Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design